Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel

FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.